Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:RCKT NASDAQ:RVNC NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$0.92+2.8%$1.20$0.82▼$4.08$241.27M0.265.61 million shs5.24 million shsRCKTRocket Pharmaceuticals$2.75+3.4%$3.32$2.40▼$5.45$290.45M0.482.38 million shs2.44 million shsRVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.78 million shsN/ASUPNSupernus Pharmaceuticals$44.41-2.5%$48.68$30.83▼$59.68$2.64B0.55539,786 shs825,357 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+2.79%-1.15%-21.65%-36.68%-74.10%RCKTRocket Pharmaceuticals+3.38%0.00%-23.61%-41.86%-9.24%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%0.00%SUPNSupernus Pharmaceuticals-2.50%-0.76%-13.53%-11.02%+33.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$0.92+2.8%$1.20$0.82▼$4.08$241.27M0.265.61 million shs5.24 million shsRCKTRocket Pharmaceuticals$2.75+3.4%$3.32$2.40▼$5.45$290.45M0.482.38 million shs2.44 million shsRVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.78 million shsN/ASUPNSupernus Pharmaceuticals$44.41-2.5%$48.68$30.83▼$59.68$2.64B0.55539,786 shs825,357 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+2.79%-1.15%-21.65%-36.68%-74.10%RCKTRocket Pharmaceuticals+3.38%0.00%-23.61%-41.86%-9.24%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%0.00%SUPNSupernus Pharmaceuticals-2.50%-0.76%-13.53%-11.02%+33.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.20Hold$4.67404.78% UpsideRCKTRocket Pharmaceuticals 2.38Hold$8.44207.07% UpsideRVNCRevance Therapeutics 0.00N/AN/AN/ASUPNSupernus Pharmaceuticals 2.43Hold$62.1739.98% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, RVNC, SUPN, and RCKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026RCKTRocket Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/6/2026AKBAAkebia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/27/2026SUPNSupernus Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/24/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/7/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026AKBAAkebia Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/30/2026RCKTRocket Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.003/27/2026SUPNSupernus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.05N/AN/A$0.12 per share7.70RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ARVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11SUPNSupernus Pharmaceuticals$718.95M3.59$3.68 per share12.06$18.52 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$1.87N/AN/AN/AN/A-69.61%-58.63%8/6/2026 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%N/ASUPNSupernus Pharmaceuticals-$38.55M-$0.51N/A12.410.97-3.74%13.07%9.66%8/4/2026 (Estimated)Latest AKBA, RVNC, SUPN, and RCKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million5/7/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41-$0.42-$0.01-$0.42$4.47 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33RCKTRocket Pharmaceuticals0.086.126.12RVNCRevance TherapeuticsN/A4.123.05SUPNSupernus PharmaceuticalsN/A1.961.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%RCKTRocket Pharmaceuticals98.39%RVNCRevance Therapeutics97.70%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%RCKTRocket Pharmaceuticals21.30%RVNCRevance Therapeutics5.10%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableRCKTRocket Pharmaceuticals240109.19 million85.94 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionNo DataSUPNSupernus Pharmaceuticals58058.04 million52.93 millionOptionableAKBA, RVNC, SUPN, and RCKT HeadlinesRecent News About These CompaniesSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Recommendation of "Hold" by AnalystsJune 10 at 4:17 AM | americanbankingnews.comSupernus Pharmaceuticals to Participate in June Investor ConferencesMay 27, 2026 | markets.businessinsider.comSupernus Pharmaceuticals to Participate in June Investor ConferencesMay 27, 2026 | globenewswire.comSupernus CVR Milestone Triggers Cash Outflow And Undervalued Stock DebateMay 25, 2026 | finance.yahoo.comSupernus Reaches Milestone, Triggers Contingent Value Rights PaymentMay 20, 2026 | tipranks.com3 growth stocks we approach with cautionMay 15, 2026 | msn.com5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings CallMay 15, 2026 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care ConferenceMay 6, 2026 | globenewswire.comDoes Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?May 6, 2026 | finance.yahoo.comSUPN Q1 deep dive: Growth products drive revenue upside, guidance highlights execution challengesMay 6, 2026 | msn.comSupernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat EstimatesMay 6, 2026 | finance.yahoo.comSupernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comSupernus Pharmaceuticals Earnings Call Signals Growth MomentumMay 5, 2026 | tipranks.comSupernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 5, 2026 | zacks.comSupernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comSupernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 EarningsMay 5, 2026 | quiverquant.comQSupernus Announces First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comSupernus Pharmaceuticals Q1 2026 earnings previewMay 5, 2026 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Neogen (NEOG), Supernus Pharmaceuticals (SUPN)April 29, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, RVNC, SUPN, and RCKT Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$0.92 +0.03 (+2.79%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.92 -0.01 (-1.03%) As of 06/12/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Rocket Pharmaceuticals NASDAQ:RCKT$2.75 +0.09 (+3.38%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.73 -0.02 (-0.62%) As of 06/12/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Revance Therapeutics NASDAQ:RVNCRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Supernus Pharmaceuticals NASDAQ:SUPN$44.41 -1.14 (-2.50%) As of 06/12/2026 04:00 PM EasternSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
